1993
Unilateral Transplantation of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Patients With Parkinson's Disease
SPENCER D, ROBBINS R, NAFTOLIN F, MAREK K, VOLLMER T, LERANTH C, ROTH R, PRICE L, GJEDDE A, BUNNEY B, SASS K, ELSWORTH J, KIER E, MAKUCH R, HOFFER P, REDMOND D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Patients With Parkinson's Disease. Obstetrical & Gynecological Survey 1993, 48: 413-415. DOI: 10.1097/00006254-199306000-00013.Peer-Reviewed Original Research
1988
Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients
Goldstein M, Lieberman A, Helmer E, Koslow M, Ransohoff J, Elsworth J, Roth R, Deutch A. Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients. Annals Of Neurology 1988, 24: 685-688. PMID: 2904793, DOI: 10.1002/ana.410240517.Peer-Reviewed Original ResearchConceptsBiopsy samplesAdrenal transplantationDopamine functionAutologous adrenal transplantationMetabolite homovanillic acidEnzyme tyrosine hydroxylaseConcentration of dopamineParkinsonian patientsTherapeutic responseHomovanillic acidParkinson's diseaseTyrosine hydroxylasePostmortem valuesBiochemical analysisBiochemical parametersPatientsTransplantationPostmortem changesDisease
1983
Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of clonidine and imipramine
Ko G, Elsworth J, Roth R, Rifkin B, Leigh H, Redmond E. Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of clonidine and imipramine. Journal Of Clinical Psychopharmacology 1983, 3: 328. DOI: 10.1097/00004714-198310000-00029.Peer-Reviewed Original ResearchPanic-Induced Elevation of Plasma MHPG Levels in Phobic-Anxious Patients: Effects of Clonidine and Imipramine
Ko G, Elsworth J, Roth R, Rifkin B, Leigh H, Redmond D. Panic-Induced Elevation of Plasma MHPG Levels in Phobic-Anxious Patients: Effects of Clonidine and Imipramine. JAMA Psychiatry 1983, 40: 425-430. PMID: 6838322, DOI: 10.1001/archpsyc.1983.01790040079011.Peer-Reviewed Original ResearchConceptsPlasma MHPG levelsMHPG levelsEffects of clonidineSignificant symptom reductionPlasma MHPG concentrationSelf-rated anxietyPlacebo treatmentCrossover trialMHPG concentrationsPlasma levelsNoradrenergic activityDrug treatmentDrug trialsSymptom reductionDiminished suppressionPanic attacksPanic symptomsImipramine hydrochlorideClonidinePatientsPhobic stimuliImipramineTrialsAnxietyTreatment
1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor